Bart Jan Kullberg

List of Publications by Year
in descending order

341	44,339	2423	2274
papers	citations	97 h-index	200 g-index

345	345	345	39268
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 503-535.	2.9	2,644
3	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	2.9	1,429
4	ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clinical Microbiology and Infection, 2012, 18, 19-37.	2.8	977
5	Invasive Candidiasis. New England Journal of Medicine, 2015, 373, 1445-1456.	13.9	962
6	Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection, 2018, 24, e1-e38.	2.8	942
7	Candida albicans Infection Affords Protection against Reinfection via Functional Reprogramming of Monocytes. Cell Host and Microbe, 2012, 12, 223-232.	5.1	926
8	Invasive candidiasis. Nature Reviews Disease Primers, 2018, 4, 18026.	18.1	841
9	An integrated model of the recognition of Candida albicans by the innate immune system. Nature Reviews Microbiology, 2008, 6, 67-78.	13.6	779
10	Differential requirement for the activation of the inflammasome for processing and release of IL-1Î² in monocytes and macrophages. Blood, 2009, 113, 2324-2335.	0.6	714
11	Human Dectin-1 Deficiency and Mucocutaneous Fungal Infections. New England Journal of Medicine, 2009, 361, 1760-1767.	13.9	671
12	Toll-like receptor 2 controls expansion and function of regulatory T cells. Journal of Clinical Investigation, 2006, 116, 485-494.	3.9	658
13	Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clinical Infectious Diseases, 2012, 54, 1110-1122.	2.9	649
14	Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. Journal of Clinical Investigation, 2006, 116, 1642-1650.	3.9	632
15	STAT1Mutations in Autosomal Dominant Chronic Mucocutaneous Candidiasis. New England Journal of Medicine, 2011, 365, 54-61.	13.9	614
16	Toll-Like Receptor 2 Suppresses Immunity against Candida albicans through Induction of IL-10 and Regulatory T Cells. Journal of Immunology, 2004, 172, 3712-3718.	0.4	565
17	The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity. Cell Metabolism, 2010, 12, 593-605.	7.2	558
18	Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 847-856.	4.6	526

#	Article	IF	Citations
19	Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet, The, 2005, 366, 1435-1442.	6.3	495
20	The Role of Tollâ€like Receptor (TLR) 2 and TLR4 in the Host Defense against Disseminated Candidiasis. Journal of Infectious Diseases, 2002, 185, 1483-1489.	1.9	444
21	Immune defence against Candida fungal infections. Nature Reviews Immunology, 2015, 15, 630-642.	10.6	440
22	IL-1Î² Processing in Host Defense: Beyond the Inflammasomes. PLoS Pathogens, 2010, 6, e1000661.	2.1	427
23	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	2.9	368
24	Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature Medicine, 2006, 12, 650-656.	15.2	360
25	The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. European Journal of Immunology, 2003, 33, 532-538.	1.6	336
26	Syk kinase is required for collaborative cytokine production induced through Dectinâ€1 and Tollâ€like receptors. European Journal of Immunology, 2008, 38, 500-506.	1.6	328
27	ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clinical Microbiology and Infection, 2012, 18, 9-18.	2.8	310
28	NOD2 and Toll-Like Receptors Are Nonredundant Recognition Systems of Mycobacterium tuberculosis. PLoS Pathogens, 2005, 1, e34.	2.1	304
29	Dectin-1 synergizes with TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cellular Microbiology, 2008, 10, 2058-2066.	1.1	296
30	The Macrophage Mannose Receptor Induces IL-17 in Response to Candida albicans. Cell Host and Microbe, 2009, 5, 329-340.	5.1	294
31	TLR4polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16645-16650.	3.3	293
32	Aspergillus fumigatusEvades Immune Recognition during Germination through Loss of Tollâ€like Receptorâ€4â€“Mediated Signal Transduction. Journal of Infectious Diseases, 2003, 188, 320-326.	1.9	290
33	Circulating Cytokines as Mediators of Fever. Clinical Infectious Diseases, 2000, 31, S178-S184.	2.9	283
34	ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clinical Microbiology and Infection, 2012, 18, 53-67.	2.8	280
35	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine, 2020, 46, 1524-1535.	3.9	278
36	Immune Recognition ofCandida albicansÎ²â€glucan by Dectinâ€1. Journal of Infectious Diseases, 2007, 196, 1565-1571.	1.9	277

#	Article	IF	Citations
37	ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.. Clinical Microbiology and Infection, 2012, 18, 38-52.	2.8	264
38	International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resistance Updates, 2015, 21-22, 30-40.	6.5	262
39	Nucleotide-Binding Oligomerization Domain-2 Modulates Specific TLR Pathways for the Induction of Cytokine Release. Journal of Immunology, 2005, 174, 6518-6523.	0.4	248
40	Functional Consequences of Toll-like Receptor 4 Polymorphisms. Molecular Medicine, 2008, 14, 346-352.	1.9	245
41	Antibiotic Prophylaxis and the Risk of Surgical Site Infections following Total Hip Arthroplasty: Timely Administration Is the Most Important Factor. Clinical Infectious Diseases, 2007, 44, 921-927.	2.9	244
42	Does the shape of lipid A determine the interaction of LPS with Toll-like receptors?. Trends in Immunology, 2002, 23, 135-139.	2.9	242
43	Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. Journal of Leukocyte Biology, 2004, 75, 749-755.	1.5	239
44	Early Stop Polymorphism in Human DECTINâ€1 Is Associated with IncreasedCandidaColonization in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2009, 49, 724-732.	2.9	226
45	Reactive oxygen speciesâ€“independent activation of the IL-1Î² inflammasome in cells from patients with chronic granulomatous disease. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3030-3033.	3.3	226
46	NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. European Journal of Immunology, 2004, 34, 2052-2059.	1.6	214
47	Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4478-84.	3.3	211
48	Dendritic Cell Interaction with Candida albicans Critically Depends on N-Linked Mannan. Journal of Biological Chemistry, 2008, 283, 20590-20599.	1.6	209
49	Interplay between Candida albicans and the Mammalian Innate Host Defense. Infection and Immunity, 2012, 80, 1304-1313.	1.0	206
50	Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. New England Journal of Medicine, 2016, 374, 1209-1220.	13.9	206
51	Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation and Protects Mice Against Lethal Escherichia coli and Salmonella typhimurium Endotoxemia. Journal of Immunology, 2000, 164, 2644-2649.	0.4	205
52	Toll-like receptors as an escape mechanism from the host defense. Trends in Microbiology, 2004, 12, 484-488.	3.5	201
53	Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infectious Diseases, 2014, 14, 166.	1.3	195
54	Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.. Journal of Clinical Investigation, 1996, 97, 1366-1372.	3.9	194

#	Article	IF	Citations
55	CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. Journal of Clinical Investigation, 2013, 123, 5035-5051.	3.9	190
56	Inflammasome-Independent Modulation of Cytokine Response by Autophagy in Human Cells. PLoS ONE, 2011, 6, e18666.	1.1	182
57	Increased Production of Interleukin 4 by CD4+and CD8+T Cells from Patients with Tuberculosis Is Related to the Presence of Pulmonary Cavities. Journal of Infectious Diseases, 2000, 181, 1194-1197.	1.9	176
58	Influenza-associated Aspergillosis in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 524-527.	2.5	176
59	Differential Cytokine Production and Toll-Like Receptor Signaling Pathways by Candida albicans Blastoconidia and Hyphae. Infection and Immunity, 2005, 73, 7458-7464.	1.0	175
60	From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias. Antimicrobial Agents and Chemotherapy, 2005, 49, 3991-3996.	1.4	173
61	Recognition and Blocking of Innate Immunity Cells by Candida albicans Chitin. Infection and Immunity, 2011, 79, 1961-1970.	1.0	172
62	Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing?. Trends in Immunology, 2003, 24, 254-258.	2.9	171
63	Ocular Manifestations of Candidemia. Clinical Infectious Diseases, 2011, 53, 262-268.	2.9	171
64	The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae ofCandida albicans. Journal of Leukocyte Biology, 2011, 90, 357-366.	1.5	169
65	Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nature Communications, 2013, 4, 1342.	5.8	157
66	Endogenous Interleukin (IL)â€“1Î± and ILâ€1Î² Are Crucial for Host Defense against Disseminated Candidiasis. Journal of Infectious Diseases, 2006, 193, 1419-1426.	1.9	150
67	Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Medicine, 2009, 35, 55-62.	3.9	148
68	Recombinant Interferon-Â Enhances Resistance to Acute Disseminated Candida albicans Infection in Mice. Journal of Infectious Diseases, 1993, 168, 436-443.	1.9	147
69	Recommendations for antibacterial therapy in adults with COVID-19 â€“ an evidence based guideline. Clinical Microbiology and Infection, 2021, 27, 61-66.	2.8	147
70	Hostâ€“microbe interactions: innate pattern recognition of fungal pathogens. Current Opinion in Microbiology, 2008, 11, 305-312.	2.3	140
71	Mycobacterium paratuberculosisis recognized by Toll-like receptors and NOD2. Journal of Leukocyte Biology, 2007, 82, 1011-1018.	1.5	133
72	The Role of Hyperuricemia in the Increased Cytokine Production After Lipopolysaccharide Challenge in Neutropenic Mice. Blood, 1997, 89, 577-582.	0.6	129

#	Article	IF	Citations
73	The inflammasome drives protective Th1 and Th17 cellular responses in disseminated candidiasis. European Journal of Immunology, 2011, 41, 2260-2268.	1.6	126
74	Adherence to local hospital guidelines for surgical antimicrobial prophylaxis: a multicentre audit in Dutch hospitals. Journal of Antimicrobial Chemotherapy, 2003, 51, 1389-1396.	1.3	125
75	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	2.5	123
76	Pro-inflammatory cytokines in patients with essential hypertension. European Journal of Clinical Investigation, 2001, 31, 31-36.	1.7	121
77	¹⁸F-FDG PET/CT for Detection of Metastatic Infection in Gram-Positive Bacteremia. Journal of Nuclear Medicine, 2010, 51, 1234-1240.	2.8	121
78	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. Clinical Infectious Diseases, 2019, 68, 1981-1989.	2.9	120
79	Recognition of fungal pathogens by Toll-like receptors. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 672-6.	1.3	119
80	Aspergillus fumigatus Conidial Melanin Modulates Host Cytokine Response. Immunobiology, 2010, 215, 915-920.	0.8	119
81	Purpura Fulminans and Symmetrical Peripheral Gangrene Caused by Capnocytophaga canimorsus (Formerly DF-2) Septicemiaâ€"A Complication of Dog Bite. Medicine (United States), 1991, 70, 287-292.	0.4	118
82	Voriconazole Salvage Treatment of Invasive Candidiasis. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 651-655.	1.3	118
83	Recognition of Fungal Pathogens by Toll-Like Receptors. Current Pharmaceutical Design, 2006, 12, 4195-4201.	0.9	116
84	Endoplasmic Reticulum Î±-Glycosidases of Candida albicans Are Required for N Glycosylation, Cell Wall Integrity, and Normal Host-Fungus Interaction. Eukaryotic Cell, 2007, 6, 2184-2193.	3.4	116
85	Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. Journal of Infectious Diseases, 2012, 205, 934-943.	1.9	116
86	Antiâ€Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology, 2010, 130, 46-54.	2.0	115
87	Interleukin-18 induces production of proinflammatory cytokines in mice: no intermediate role for the cytokines of the tumor necrosis factor family and interleukin-1Î². European Journal of Immunology, 2000, 30, 3057-3060.	1.6	114
88	European expert opinion on the management of invasive candidiasis in adults. Clinical Microbiology and Infection, 2011, 17, 1-12.	2.8	113
89	Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-? production and toll-like receptor 4 expression. Arthritis and Rheumatism, 2003, 48, 1853-1857.	6.7	111
90	The Y238X Stop Codon Polymorphism in the Human Î²-Glucan Receptor Dectin-1 and Susceptibility to Invasive Aspergillosis. Journal of Infectious Diseases, 2011, 203, 736-743.	1.9	111

#	Article	IF	Citations
91	EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clinical Infectious Diseases, 2021, 72, S121-S127.	2.9	109
92	Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infection and Immunity, 1990, 58, 3319-3324.	1.0	107
93	Quality improvement of surgical prophylaxis in Dutch hospitals: evaluation of a multi-site intervention by time series analysis. Journal of Antimicrobial Chemotherapy, 2005, 56, 1094-1102.	1.3	106
94	A Multifunctional Mannosyltransferase Family in Candida albicans Determines Cell Wall Mannan Structure and Host-Fungus Interactions. Journal of Biological Chemistry, 2010, 285, 12087-12095.	1.6	106
95	Non-LPS components ofChlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. European Journal of Immunology, 2002, 32, 1188-1195.	1.6	103
96	STAT1 Hyperphosphorylation and Defective IL12R/IL23R Signaling Underlie Defective Immunity in Autosomal Dominant Chronic Mucocutaneous Candidiasis. PLoS ONE, 2011, 6, e29248.	1.1	101
97	Modulation of Toll-Like Receptor 2 (TLR2) and TLR4 Responses byAspergillus fumigatus. Infection and Immunity, 2009, 77, 2184-2192.	1.0	100
98	Genetic susceptibility to Candida infections. EMBO Molecular Medicine, 2013, 5, 805-813.	3.3	100
99	Role of Dectin-2 for Host Defense against Systemic Infection with Candida glabrata. Infection and Immunity, 2014, 82, 1064-1073.	1.0	100
100	Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. Journal of Leukocyte Biology, 2010, 88, 227-232.	1.5	97
101	Barriers to optimal antibiotic use for community-acquired pneumonia at hospitals: a qualitative study. Quality and Safety in Health Care, 2007, 16, 143-149.	2.5	95
102	The effect of reninâ€“angiotensin system inhibitors on proâ€•and antiâ€inflammatory cytokine production. Immunology, 1998, 94, 376-379.	2.0	93
103	Acellular components ofChlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. European Journal of Immunology, 2000, 30, 541-549.	1.6	93
104	Two Patients with Cryptococcal Meningitis and Idiopathic CD4 Lymphopenia: Defective Cytokine Production and Reversal by Recombinant Interferon-Â Therapy. Clinical Infectious Diseases, 2004, 39, e83-e87.	2.9	93
105	Aspergillus fumigatus cell wall components differentially modulate host TLR2 and TLR4 responses. Microbes and Infection, 2011, 13, 151-159.	1.0	93
106	Metastatic Infectious Disease and Clinical Outcome in Staphylococcus aureus and Streptococcus species Bacteremia. Medicine (United States), 2012, 91, 86-94.	0.4	91
107	ESCMID guideline for the diagnosis and management of Candida diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. Clinical Microbiology and Infection, 2012, 18, 1-8.	2.8	91
108	Th17 responses and host defense against microorganisms: an overview. BMB Reports, 2009, 42, 776-787.	1.1	91

#	Article	IF	Citations
109	Optimizing antimicrobial therapy. A method for antimicrobial drug me evaluation. Journal of Antimicrobial Chemotherapy, 1992, 30, 724-727.	1.3	87
110	Role of TLR1 and TLR6 in the host defense against disseminated candidiasis. FEMS Immunology and Medical Microbiology, 2008, 52, 118-123.	2.7	87
111	Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 10272-10277.	3.3	87
112	Lyme borreliosis: diagnosis and management. BMJ, The, 2020, 369, m1041.	3.0	85
113	Cost-Effectiveness of Routine¹⁸F-FDG PET/CT in High-Risk Patients with Gram-Positive Bacteremia. Journal of Nuclear Medicine, 2011, 52, 1673-1678.	2.8	84
114	Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. Journal of Leukocyte Biology, 2006, 79, 860-866.	1.5	83
115	ESCMID guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. Clinical Microbiology and Infection, 2012, 18, 68-77.	2.8	81
116	Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia. Journal of Infectious Diseases, 2011, 204, 1138-1145.	1.9	80
117	Candida albicans Dampens Host Defense by Downregulating IL-17 Production. Journal of Immunology, 2010, 185, 2450-2457.	0.4	78
118	Early treatment of candidemia in adults: a review. Medical Mycology, 2011, 49, 113-120.	0.3	78
119	Bartonella quintanaLipopolysaccharide Is a Natural Antagonist of Toll-Like Receptor 4. Infection and Immunity, 2007, 75, 4831-4837.	1.0	76
120	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nature Communications, 2014, 5, 4675.	5.8	76
121	Selective digestive decontamination in patients in intensive care. Journal of Antimicrobial Chemotherapy, 2000, 46, 351-362.	1.3	75
122	Transcriptional and inflammasomeâ€mediated pathways for the induction of ILâ€1Î² production by Mycobacterium tuberculosis. European Journal of Immunology, 2009, 39, 1914-1922.	1.6	75
123	Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Medicine, 2009, 35, 206-214.	3.9	75
124	Pathogenesis of invasive candidiasis. Current Opinion in Critical Care, 2010, 16, 453-459.	1.6	75
125	Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nature Microbiology, 2020, 5, 1516-1531.	5.9	75
126	Fungal strategies for overcoming host innate immune response. Medical Mycology, 2009, 47, 227-236.	0.3	74

#	Article	IF	Citations
127	Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis. Journal of Clinical Microbiology, 2012, 50, 2330-2336.	1.8	74
128	Effects of Hydrophobicity on the Antifungal Activity of Î±â€Helical Antimicrobial Peptides. Chemical Biology and Drug Design, 2008, 72, 483-495.	1.5	73
129	The Candida Th17 response is dependent on mannan- and Â-glucan-induced prostaglandin E2. International Immunology, 2010, 22, 889-895.	1.8	73
130	Pharmacologic Inhibitors of Tumor Necrosis Factor Production Exert Differential Effects in Lethal Endotoxemia and in Infection with Live Microorganisms in Mice. Journal of Infectious Diseases, 1995, 171, 393-399.	1.9	72
131	Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts. Critical Care, 2010, 14, R103.	2.5	72
132	CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. Science Translational Medicine, 2016, 8, 322ra10.	5.8	71
133	Bypassing Pathogenâ€Induced Inflammasome Activation for the Regulation of Interleukinâ€1Î² Production by the Fungal PathogenCandida albicans. Journal of Infectious Diseases, 2009, 199, 1087-1096.	1.9	70
134	¹⁸F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. Journal of Nuclear Medicine, 2017, 58, 1504-1510.	2.8	70
135	Engagement of NOD2 has a dual effect on proILâ€1Î² mRNA transcription and secretion of bioactive ILâ€1Î². European Journal of Immunology, 2008, 38, 184-191.	1.6	69
136	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 963-974.	1.3	69
137	Apolipoprotein E-deficient mice have an impaired immune response toKlebsiella pneumoniae. European Journal of Clinical Investigation, 2000, 30, 818-822.	1.7	68
138	Tailored Interventions to Improve Antibiotic Use for Lower Respiratory Tract Infections in Hospitals: A Cluster-Randomized, Controlled Trial. Clinical Infectious Diseases, 2007, 44, 931-941.	2.9	68
139	Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. Clinical Infectious Diseases, 2012, 54, 502-510.	2.9	68
140	The Role of Endogenous Interleukin (IL)â€“18, ILâ€12, ILâ€1Î², and Tumor Necrosis Factorâ€Î± in the Production of Interferonâ€Î³ Induced byCandida albicansin Human Wholeâ€Blood Cultures. Journal of Infectious Diseases, 2002, 185, 963-970.	1.9	67
141	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. European Journal of Clinical Investigation, 2004, 34, 94-99.	1.7	66
142	1,25-dihydroxyvitamin D3 Modulates Cytokine Production Induced by Candida albicans: Impact of Seasonal Variation of Immune Responses. Journal of Infectious Diseases, 2011, 203, 122-130.	1.9	66
143	Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis. Frontiers in Microbiology, 2014, 5, 483.	1.5	66
144	Recognition ofBorrelia burgdorferiby NOD2 Is Central for the Induction of an Inflammatory Reaction. Journal of Infectious Diseases, 2010, 201, 1849-1858.	1.9	64

#	Article	IF	Citations
145	Variable recognition ofCandida albicansstrains by TLR4 and lectin recognition receptors. Medical Mycology, 2010, 48, 897-903.	0.3	64
146	Understanding human immune function using the resources from the Human Functional Genomics Project. Nature Medicine, 2016, 22, 831-833.	15.2	63
147	Increased susceptibility to systemic candidiasis in interleukin-6 deficient mice 1. Medical Mycology, 1999, 37, 419-426.	0.3	62
148	Trends in immunotherapy of fungal infections. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 51-55.	1.3	60
149	Phagocytosis and intracellular killing of Candida albicans blastoconidia by neutrophils and macrophages: a comparison of different microbiological test systems. Journal of Microbiological Methods, 2002, 49, 55-62.	0.7	60
150	Antibiotic research and development: business as usual?. Journal of Antimicrobial Chemotherapy, 2015, 70, 1604-7.	1.3	60
151	BACTERIAL LIPOPOLYSACCHARIDE BINDS AND STIMULATES CYTOKINE-PRODUCING CELLS BEFORE NEUTRALIZATION BY ENDOGENOUS LIPOPROTEINS CAN OCCUR. Cytokine, 1998, 10, 766-772.	1.4	58
152	Functional consequences of the Asp299Gly Toll-like receptor-4 polymorphism. Cytokine, 2005, 30, 264-268.	1.4	58
153	Cytokine responses and regulation of interferon-gamma release by human mononuclear cells toAspergillus fumigatusand other filamentous fungi. Medical Mycology, 2005, 43, 613-621.	0.3	58
154	Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Netherlands Journal of Medicine, 2018, 76, 4-13.	0.6	58
155	The role of NLRs and TLRs in the activation of the inflammasome. Expert Opinion on Biological Therapy, 2008, 8, 1867-1872.	1.4	57
156	Severe Candida spp. infections: new insights into natural immunity. International Journal of Antimicrobial Agents, 2010, 36, S58-S62.	1.1	57
157	ICU-acquired immunosuppression and the risk for secondary fungal infections. Medical Mycology, 2011, 49, S17-S23.	0.3	57
158	Complement plays a central role in <scp>C</scp>andida albicansâ€induced cytokine production by human <scp>PBMC</scp>s. European Journal of Immunology, 2012, 42, 993-1004.	1.6	57
159	Candida albicans Primes TLR Cytokine Responses through a Dectin-1/Raf-1â€“Mediated Pathway. Journal of Immunology, 2013, 190, 4129-4135.	0.4	57
160	TLR1/TLR2 Heterodimers Play an Important Role in the Recognition of Borrelia Spirochetes. PLoS ONE, 2011, 6, e25998.	1.1	57
161	Recombinant Murine Granulocyte Colonyâ€Stimulating Factor Protects against Acute DisseminatedCandida albicansInfection in Nonneutropenic Mice. Journal of Infectious Diseases, 1998, 177, 175-181.	1.9	56
162	Quality of Antibiotic Use for Lower Respiratory Tract Infections at Hospitals: (How) Can We Measure It?. Clinical Infectious Diseases, 2005, 41, 450-460.	2.9	56

#	Article	IF	Citations
163	Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. International Journal of Obesity, 2008, 32, 1407-1414.	1.6	56
164	Modulation of neutrophil function in host defense against disseminatedCandida albicansinfection in mice. FEMS Immunology and Medical Microbiology, 1999, 26, 299-307.	2.7	55
165	Deeply invasive candidiasis. Infectious Disease Clinics of North America, 2002, 16, 821-835.	1.9	55
166	Amphotericin B versus amphotericin B plus 5-flucytosine: Poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection, 1994, 22, 81-85.	2.3	54
167	TREM-1 interaction with the LPS/TLR4 receptor complex. European Cytokine Network, 2011, 22, 11-14.	1.1	54
168	The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases. BMC Immunology, 2014, 15, 55.	0.9	54
169	Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology, 2003, 110, 329-334.	2.0	53
170	Human dendritic cells are less potent at killing Candida albicans than both monocytes and macrophages. Microbes and Infection, 2004, 6, 985-989.	1.0	53
171	Crohnâ€™s disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology, 2008, 123, 600-605.	2.0	53
172	Early Proinflammatory Cytokines and Câ€Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis. Journal of Infectious Diseases, 2010, 202, 1454-1462.	1.9	52
173	Association of a variable number tandem repeat in the NLRP3 gene in women with susceptibility to RVVC. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 797-801.	1.3	51
174	CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. European Journal of Immunology, 2002, 32, 1455.	1.6	50
175	Complicating infectious foci in patients with Staphylococcus aureus or Streptococcus species bacteraemia. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 105-113.	1.3	50
176	Receptor Recognition of and Immune Intracellular Pathways for Veillonella parvula Lipopolysaccharide. Vaccine Journal, 2009, 16, 1804-1809.	3.2	50
177	The role of nurses in the recognition and treatment of patients with sepsis in the emergency department: A prospective before-and-after intervention study. International Journal of Nursing Studies, 2010, 47, 1464-1473.	2.5	50
178	Differential role of IL-18 and IL-12 in the host defense against disseminatedCandida albicans infection. European Journal of Immunology, 2003, 33, 3409-3417.	1.6	49
179	Detection of the Candida Antigen Mannan in Cerebrospinal Fluid Specimens from Patients Suspected of Having Candida Meningitis. Journal of Clinical Microbiology, 2004, 42, 867-870.	1.8	49
180	Activation ofÂinnate host defense mechanisms byÂBorrelia. European Cytokine Network, 2010, 21, 7-18.	1.1	49

#	Article	IF	Citations
181	Genetic Variation of Innate Immune Genes in HIV-Infected African Patients With or Without Oropharyngeal Candidiasis. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 87-94.	0.9	48
182	18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 120-128.	3.3	48
183	Role of Interleukin-18 in Host Defense against Disseminated Candida albicans Infection. Infection and Immunity, 2002, 70, 3284-3286.	1.0	46
184	Cytokine Release in Healthy Donors and Patients with Chronic Granulomatous Disease upon Stimulation with Aspergillus fumigatus. Scandinavian Journal of Infectious Diseases, 2003, 35, 482-487.	1.5	46
185	Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors. Journal of Antimicrobial Chemotherapy, 2005, 56, 575-582.	1.3	46
186	Host defence against disseminatedCandida albicansinfection and implications for antifungal immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 891-903.	1.4	46
187	Redundant role of TLR9 for anti-Candida host defense. Immunobiology, 2008, 213, 613-620.	0.8	46
188	Improved Survival of TNF-Deficient Mice During the Zymosan-Induced Multiple Organ Dysfunction Syndrome. Shock, 2002, 17, 468-472.	1.0	45
189	The classical CD14⁺⁺CD16^{â˜} monocytes, but not the patrolling CD14⁺CD16⁺ monocytes, promote Th17 responses to Candida albicans. European Journal of Immunology, 2011, 41, 2915-2924.	1.6	45
190	Serial and panel analyses of biomarkers do not improve the prediction of bacteremia compared to one procalcitonin measurement. Journal of Infection, 2012, 65, 292-301.	1.7	45
191	Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis. Journal of Immunological Methods, 1999, 222, 145-153.	0.6	44
192	Functional and Genomic Architecture of Borrelia burgdorferi -Induced Cytokine Responses in Humans. Cell Host and Microbe, 2016, 20, 822-833.	5.1	44
193	ChlamydiapneumoniaeStimulates IFN-Î³ Synthesis through MyD88-Dependent, TLR2- and TLR4-Independent Induction of IL-18 Release. Journal of Immunology, 2004, 173, 1477-1482.	0.4	43
194	Mycoviruses: future therapeutic agents of invasive fungal infections in humans?. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 755-763.	1.3	43
195	Genetic Basis for Recurrent Vulvo-Vaginal Candidiasis. Current Infectious Disease Reports, 2013, 15, 136-142.	1.3	43
196	Delay in Administering the First Dose of Antibiotics in Patients Admitted to Hospital with Serious Infections. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 681-684.	1.3	41
197	Duration of Antifungal Treatment and Development of Delayed Complications in Patients with Candidaemia. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 43-48.	1.3	41
198	The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine, 2010, 28, 614-622.	1.7	40

#	Article	IF	Citations
199	Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. Journal of Antimicrobial Chemotherapy, 1998, 42, 469-474.	1.3	39
200	An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. European Journal of Cancer, 2004, 40, 1314-1319.	1.3	39
201	Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Regional Health - Europe, The, 2022, 13, 100266.	3.0	39
202	Improving the Process of Antibiotic Therapy in Daily Practice. Archives of Internal Medicine, 2004, 164, 1206.	4.3	38
203	Novel strategies for the prevention and treatment ofCandidainfections: the potential of immunotherapy. FEMS Microbiology Reviews, 2010, 34, 1063-1075.	3.9	38
204	A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. Science Translational Medicine, 2019, 11, .	5.8	38
205	Borrelia species induce inflammasome activation and ILâ€1â€dependent mechanism. European Journal of Immunology, 2011, 41, 172-181.	1.6	37
206	Human genetic susceptibility toCandidainfections. Medical Mycology, 2012, 50, 785-794.	0.3	37
207	An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Annals of Hematology, 1995, 70, 83-87.	0.8	36
208	DIFFERENTIAL EFFECTS OF IL-17 PATHWAY IN DISSEMINATED CANDIDIASIS AND ZYMOSAN-INDUCED MULTIPLE ORGAN FAILURE. Shock, 2010, 34, 407-411.	1.0	36
209	The effects of dexamethasone and chlorpromazine on tumour necrosis factorâ€•α , interleukinâ€1 β , interleukinâ€1 receptor antagonist and interleukinâ€10 in human volunteers. Immunology, 1997, 91, 548-552.	2.0	35
210	Severely impaired IL-12/IL-18/IFNgamma axis in patients with hyper IgE syndrome. European Journal of Clinical Investigation, 2005, 35, 718-721.	1.7	35
211	Safety and Tolerability of Voriconazole in Patients with Baseline Renal Insufficiency and Candidemia. Antimicrobial Agents and Chemotherapy, 2012, 56, 3133-3137.	1.4	35
212	Autophagy is redundant for the host defense against systemic Candida albicans infections. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 711-722.	1.3	35
213	Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole. Clinical Microbiology and Infection, 2003, 9, 750-753.	2.8	34
214	Design of Efficacy Trials of Cytokines in Combination with Antifungal Drugs. Clinical Infectious Diseases, 2004, 39, S218-S223.	2.9	34
215	Nucleotide Oligomerization Domain 2 (Nod2) Is Not Involved in the Pattern Recognition of Candida albicans. Vaccine Journal, 2006, 13, 423-425.	3.2	34
216	Role of Interleukin-23 (IL-23) Receptor Signaling for IL-17 Responses in Human Lyme Disease. Infection and Immunity, 2011, 79, 4681-4687.	1.0	34

#	Article	IF	Citations
217	Utility of immune response-derived biomarkers in the differential diagnosis of inflammatory disorders. Journal of Infection, 2016, 72, 1-18.	1.7	34
218	Monitoring, documenting and reporting the quality of antibiotic use in the Netherlands: a pilot study to establish a national antimicrobial stewardship registry. BMC Infectious Diseases, 2017, 17, 565.	1.3	33
219	Delayed Clearance of Intraabdominal Abscesses Caused byCandida albicansin Tumor Necrosis Factorâ€“Î±â€“ and LymphotoxinâÎ±â€“Deficient Mice. Journal of Infectious Diseases, 2002, 186, 1815-1822.	1.9	32
220	Drosomycin-Like Defensin, a Human Homologue ofDrosophila melanogasterDrosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	1.4	32
221	LPS-induced cytokine production and expression of Î²2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis, 1998, 141, 99-105.	0.4	31
222	Effect of Optimized Antibiotic Prophylaxis on the Incidence of Surgical Site Infection. Infection Control and Hospital Epidemiology, 2006, 27, 1340-1346.	1.0	31
223	Milder clinical hyperimmunoglobulin E syndrome phenotype is associated with partial interleukin-17 deficiency. Clinical and Experimental Immunology, 2010, 159, 57-64.	1.1	31
224	Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study. Lancet Regional Health - Europe, The, 2021, 6, 100142.	3.0	31
225	Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrobial Agents and Chemotherapy, 1992, 36, 1225-1229.	1.4	30
226	Cytokines as therapy for opportunistic fungal infections. Research in Immunology, 1998, 149, 478-488.	0.9	30
227	Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study. BMC Infectious Diseases, 2017, 17, 321.	1.3	30
228	Recombinant Interleukinâ€18 Protects against DisseminatedCandida albicansInfection in Mice. Journal of Infectious Diseases, 2004, 189, 1524-1527.	1.9	29
229	Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. Medical Mycology, 2004, 42, 341-348.	0.3	29
230	¹⁸F-FDG PET/CTâ€“Guided Treatment Duration in Patients with High-Risk Staphylococcus Aureus Bacteremia: A Proof of Principle. Journal of Nuclear Medicine, 2019, 60, 998-1002.	2.8	27
231	Phospholipase A2 Is a Circulating Mediator in Typhoid Fever. Journal of Infectious Diseases, 1995, 172, 305-308.	1.9	26
232	Proinflammatory Cytokines and Treatment of Disease. Annals of the New York Academy of Sciences, 1998, 856, 243-251.	1.8	26
233	Differential Roles of Interleukin-18 (IL-18) and IL-12 for Induction of Gamma Interferon by Staphylococcal Cell Wall Components and Superantigens. Infection and Immunity, 2001, 69, 5025-5030.	1.0	26
234	Lipoprotein(a) Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Production by Human Mononuclear Cells. Infection and Immunity, 1998, 66, 2365-2367.	1.0	26

#	Article	IF	Citations
235	Helicobacter cinaedi Bacteremia Associated with Localized Pain but Not with Cellulitis. Clinical Infectious Diseases, 1996, 22, 710-711.	2.9	25
236	Lipopolysaccharideâ€induced production of tumour necrosis factor and interleukinâ€1 is differentially regulated at the receptor level: the role of CD14â€dependent and CD14â€independent pathways. Immunology, 1998, 94, 340-344.	2.0	25
237	Non-adherence to antimicrobial treatment guidelines results in more broad-spectrum but not more appropriate therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1561-1568.	1.3	25
238	Parenteral Administration of Medium- but Not Long-Chain Lipid Emulsions May Increase the Risk for Infections by Candida albicans. Infection and Immunity, 2002, 70, 6471-6474.	1.0	24
239	Regulation of Staphylococcus epidermidis-induced IFN-Î³ in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine, 2003, 21, 65-73.	1.4	24
240	Differential susceptibility to lethal endotoxaemia in mice deficient in ILâ€1Î±, ILâ€1Î² or ILâ€1 receptor type I. Apmis, 2010, 118, 1000-1007.	0.9	24
241	Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials. Journal of Antimicrobial Chemotherapy, 2017, 72, 2368-2377.	1.3	24
242	Human resources required for antimicrobial stewardship teams: a Dutch consensus report. Clinical Microbiology and Infection, 2018, 24, 1273-1279.	2.8	24
243	Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. Neurology, 2019, 92, e1447-e1455.	1.5	24
244	An integrative genomics approach identifies novel pathways that influence candidaemia susceptibility. PLoS ONE, 2017, 12, e0180824.	1.1	24
245	Micrograniulomatous Aspergillosis in a Patient with Chronic Granulomatous Disease: Cure with Voriconazole. Clinical Infectious Diseases, 1998, 26, 996-997.	2.9	23
246	Earlier Initiation of Antibiotic Treatment for Severe Infections After Interventions to Improve the Organization and Specific Guidelines in the Emergency Department. Archives of Internal Medicine, 2000, 160, 1317.	4.3	23
247	Immunotherapy. Current Opinion in Infectious Diseases, 2014, 27, 511-516.	1.3	23
248	Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infectious Diseases, 2015, 15, 140.	1.3	23
249	Adoption of a national antimicrobial guide (SWAB-ID) in the Netherlands. European Journal of Clinical Pharmacology, 2016, 72, 249-252.	0.8	23
250	Circulating Lipoproteins Are a Crucial Component of Host Defense against Invasive Salmonella typhimurium Infection. PLoS ONE, 2009, 4, e4237.	1.1	23
251	An electronic trigger tool to optimise intravenous to oral antibiotic switch: a controlled, interrupted time series study. Antimicrobial Resistance and Infection Control, 2017, 6, 81.	1.5	22
252	Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine, 2005, 30, 72-77.	1.4	21

#	Article	IF	Citations
253	Quality Indicators for Appropriate Outpatient Parenteral Antimicrobial Therapy in Adults: A Systematic Review and RAND-modified Delphi Procedure. Clinical Infectious Diseases, 2020, 70, 1075-1082.	2.9	21
254	The Impact of Nontuberculous Myobacteria on Management of Presumed Pulmonary Tuberculosis. Infection, 2001, 29, 59-63.	2.3	20
255	Cytokine Responses to Fungal Pathogens in Kupffer Cells are Toll-like Receptor 4 Independent and Mediated by Tyrosine Kinases. Scandinavian Journal of Immunology, 2005, 62, 148-154.	1.3	20
256	An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. Journal of Antimicrobial Chemotherapy, 2013, 68, 1655-1659.	1.3	20
257	Quality of outpatient parenteral antimicrobial therapy (OPAT) care from the patientâ€™s perspective: a qualitative study. BMJ Open, 2018, 8, e024564.	0.8	20
258	Prevalence and determinants of persistent symptoms after treatment for Lyme borreliosis: study protocol for an observational, prospective cohort study (LymeProspect). BMC Infectious Diseases, 2019, 19, 324.	1.3	20
259	Do only circulating pyrogenic cytokines act as mediators in the febrile response? A hypothesis. European Journal of Clinical Investigation, 1999, 29, 351-356.	1.7	19
260	Proinflammatory Cytokines in the Treatment of Bacterial and Fungal Infections. BioDrugs, 2004, 18, 9-22.	2.2	19
261	Candida albicans Releases Soluble Factors That Potentiate Cytokine Production by Human Cells through a Protease-Activated Receptor 1- and 2-Independent Pathway. Infection and Immunity, 2010, 78, 393-399.	1.0	19
262	Patient Susceptibility to Candidiasisâ€”A Potential for Adjunctive Immunotherapy. Journal of Fungi (Basel, Switzerland), 2018, 4, 9.	1.5	19
263	Fasâ€FasL Interactions Modulate Host Defense against SystemicCandida albicansInfection. Journal of Infectious Diseases, 1999, 180, 1648-1655.	1.9	18
264	Voriconazole or Amphotericin B as Primary Therapy Yields Distinct Early Serum Galactomannan Trends Related to Outcomes in Invasive Aspergillosis. PLoS ONE, 2014, 9, e90176.	1.1	18
265	Increased interleukin-1Î± and interleukin-1Î² production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. Immunology, 1998, 95, 466.	2.0	18
266	No effect of recombinant human interleukin-1 on numbers of peripheral blood and peritoneal leukocytes during acute inflammation. Inflammation, 1991, 15, 457-470.	1.7	17
267	Infusion of Lipoproteins into Volunteers Enhances the Growth of Candida albicans. Clinical Infectious Diseases, 1999, 28, 1148-1151.	2.9	17
268	Role of autophagy genetic variants for the risk of Candida infections. Medical Mycology, 2014, 52, 333-341.	0.3	17
269	A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans. Journal of Infectious Diseases, 2019, 220, 862-872.	1.9	17
270	Cytokines in the treatment of fungal infections. Biotherapy (Dordrecht, Netherlands), 1994, 7, 195-210.	0.7	16

#	Article	IF	Citations
271	REGULATION OF THE PRODUCTION OF PRO-INFLAMMATORY CYTOKINES AND ANTAGONISTS DURING CHEMOTHERAPY-INDUCED NEUTROPENIA IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES. Cytokine, 1997, 9, 702-710.	1.4	16
272	Therapy of invasive fungal infections. Netherlands Journal of Medicine, 1999, 55, 118-127.	0.6	16
273	Acute disseminated encephalomyelitis associated with Borrelia burgdorferi. Journal of Neurology, 2004, 251, 626-629.	1.8	16
274	Both TLR2 and TLR4 are involved in the recognition of Candida albicans. Reply to â€œTLR2, but not TLR4, triggers cytokine production by murine cells in response to Candida albicans yeasts and hyphaeâ€•by Gil and Gozalbo, Microbes and Infection 8 (2006) 2823â€“2824. Microbes and Infection, 2006, 8, 2821-2822.	1.0	16
275	Cytokine production from stimulated whole blood cultures inÂrheumatoid arthritis patients treated withÂvarious TNF blocking agents. European Cytokine Network, 2009, 20, 88-93.	1.1	16
276	A survey on antimicrobial stewardship prerequisites, objectives and improvement strategies: systematic development and nationwide assessment in Dutch acute care hospitals. Journal of Antimicrobial Chemotherapy, 2018, 73, 3496-3504.	1.3	16
277	Use of fluconazole in daily practice: still room for improvement. Journal of Antimicrobial Chemotherapy, 2001, 48, 303-310.	1.3	15
278	Native LDL potentiate TNFÎ± and IL-8 production by human mononuclear cells. Journal of Lipid Research, 2002, 43, 1065-1071.	2.0	15
279	Immune response toAspergillus fumigatusin compromised hosts: from bedside to bench. Future Microbiology, 2011, 6, 73-83.	1.0	15
280	Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) - design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis. BMC Infectious Diseases, 2014, 14, 543.	1.3	15
281	Epithelial Sensing of Fungal Invasion. Cell Host and Microbe, 2010, 8, 219-220.	5.1	14
282	The impact of caspase-12 on susceptibility to candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 277-280.	1.3	14
283	Phagocytosis and Intracellular Killing of Candida albicans by Murine Polymorphonuclear Neutrophils. Methods in Molecular Biology, 2012, 845, 277-287.	0.4	13
284	Validation of cellular tests for Lyme borreliosis (VICTORY) study. BMC Infectious Diseases, 2019, 19, 732.	1.3	13
285	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	1.8	13
286	Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Clinical Infectious Diseases, 1998, 26, 1482-1483.	2.9	12
287	Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study. European Journal of Cancer, 2019, 113, 32-40.	1.3	12
288	The Janus face of Bartonella quintana recognition by Toll-like receptors (TLRs): a review. European Cytokine Network, 2008, 19, 113-8.	1.1	12

#	Article	IF	Citations
289	Immunomodulators in Bacterial and Fungal Infections. BioDrugs, 1994, 1, 43-55.	0.7	11
290	Increased voluntary exercise in mice deficient for tumour necrosis factor-? and lymphotoxin-?. European Journal of Clinical Investigation, 2007, 37, 737-741.	1.7	11
291	An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis. Journal of Infectious Diseases, 2022, 225, 1796-1806.	1.9	11
292	Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy (Dordrecht, Netherlands), 1994, 7, 161-167.	0.7	10
293	Improving the quality of antimicrobial drug use can result in cost containment. International Journal of Clinical Pharmacy, 1995, 17, 163-167.	1.4	10
294	Oxidation of Lowâ€Ðensity Lipoproteins by Acellular Components ofChlamydia pneumoniae. Journal of Infectious Diseases, 2000, 181, 1868-1869.	1.9	10
295	Influence of endogenous pro-inflammatory cytokines on neutrophil-mediated damage ofCandida albicanspseudohyphae, quantified in a modified tetrazolium dye assay. Medical Mycology, 2005, 43, 551-557.	0.3	10
296	Treatment of knee prosthesis infections: evaluation of 15 patients over a 5-year period. International Orthopaedics, 2009, 33, 1249-1254.	0.9	10
297	Treatment of Intra-Abdominal Abscesses Caused by Candida albicans with Antifungal Agents and Recombinant Murine Granulocyte Colony-Stimulating Factor. Antimicrobial Agents and Chemotherapy, 2003, 47, 3688-3693.	1.4	8
298	Treatment of candidiasis: insights from host genetics. Expert Review of Anti-Infective Therapy, 2012, 10, 947-956.	2.0	8
299	Borrelia burgdorferi Is a Poor Inducer of Gamma Interferon: Amplification Induced by Interleukin-12. Infection and Immunity, 2022, 90, iai0055821.	1.0	8
300	Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. Atherosclerosis, 1999, 144, 94.	0.4	7
301	Cervical Spinal Epidural Abscess Due to Group B Streptococcus in a Previously Healthy Elderly Male. Scandinavian Journal of Infectious Diseases, 2000, 32, 577-577.	1.5	7
302	Variation in Genes of Î²-glucan Recognition Pathway and Susceptibility to Opportunistic Infections in HIV-Positive Patients. Immunological Investigations, 2011, 40, 735-750.	1.0	7
303	Adjuvant interferon-gamma immunotherapy in a patient with progressive cerebral Nocardia abscesses. International Journal of Infectious Diseases, 2017, 59, 25-28.	1.5	7
304	Evaluation of cloxacillin concentrations in plasma and muscle tissue during cardiopulmonary bypass. Scandinavian Journal of Infectious Diseases, 1991, 23, 233-238.	1.5	6
305	Immunomodulation by n-3 polyunsaturated fatty acids. Trends in Immunology, 1999, 20, 103.	7.5	6
306	Polymorphism in innate immunity genes and susceptibility to recurrent vulvovaginal candidiasis. Journal De Mycologie Medicale, 2009, 19, 191-196.	0.7	6

#	Article	IF	Citations
307	Bone-marrow uptake of 18F-FDG during fever. Lancet Infectious Diseases, The, 2010, 10, 509-510.	4.6	6
308	Immunologic defects in severe mucocutaneous HSV-2 infections: Response to IFN-Î³ therapy. Journal of Allergy and Clinical Immunology, 2016, 138, 895-898.	1.5	6
309	Neutrophils differentially attenuate immune response toAspergillusinfection through complement receptor 3 and induction of myeloperoxidase. Cellular Microbiology, 2018, 20, e12798.	1.1	6
310	Cost-effectiveness of longer-term versus shorter-term provision of antibiotics in patients with persistent symptoms attributed to Lyme disease. PLoS ONE, 2018, 13, e0195260.	1.1	6
311	Appropriate empirical antibiotic use in the emergency department: full compliance matters!. JAC-Antimicrobial Resistance, 2019, 1, dlz061.	0.9	6
312	Treatment of Fungal Infections in Surgical Patients Using Conventional Antifungals. Journal of Chemotherapy, 1999, 11, 494-503.	0.7	5
313	Host-microbe interactions in stem cell transplantation; recognizing Candida in infection and inflammation. Virulence, 2010, 1, 180-184.	1.8	5
314	Cytokine Production Assays Reveal Discriminatory Immune Defects in Adults with Recurrent Infections and Noninfectious Inflammation. Vaccine Journal, 2014, 21, 1061-1069.	3.2	5
315	Cognitive impairments in patients with persistent symptoms attributed to Lyme disease. BMC Infectious Diseases, 2019, 19, 833.	1.3	5
316	Immunological Effects of Antiâ€'IL-17/12/23 Therapy in Patients with Psoriasis Complicated by Candida Infections. Journal of Investigative Dermatology, 2022, 142, 2929-2939.e8.	0.3	5
317	Legionella infection with acute renal failure and thrombocytopenia mimicking allograft rejection: A pitfall in post-transplantation diagnosis. Transplant International, 1988, 1, 222-225.	0.8	4
318	Selecting outcome parameters in studies aimed at improving rational use of antibiotics - practical considerations. Journal of Clinical Pharmacy and Therapeutics, 2003, 28, 475-478.	0.7	4
319	Response to Gil et al.: Toll-like receptor-2 â€“ an important component of host defense. Trends in Microbiology, 2005, 13, 299-300.	3.5	4
320	Expectancies as predictors of symptom improvement after antimicrobial therapy for persistent symptoms attributed to Lyme disease. Clinical Rheumatology, 2021, 40, 4295-4308.	1.0	4
321	Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. European Journal of Immunology, 2002, 32, 1188-1195.	1.6	4
322	Modulation of the Proâ€•and Antiinflammatory Cytokines by Amphotericin B. Journal of Infectious Diseases, 1999, 180, 1408-1409.	1.9	3
323	The Initial QuantiFERON-Lyme Prototype is Unsuitable for European Patients. Clinical Infectious Diseases, 2021, 73, 1125-1126.	2.9	3
324	Multiple endocrine neoplasia type 2b with a good prognosis. Archives of Internal Medicine, 1987, 147, 1125-1127.	4.3	3

#	Article	IF	Citations
325	Pathogenesis of Fever: Are Circulating Pyrogenic Cytokines the Only Mediators?. Clinical Infectious Diseases, 1998, 26, 1479-1479.	2.9	2
326	Effect of Recombinant Murine Granulocyte Colony-Stimulating Factor with or without Fluoroquinolone Therapy on Mixed-Infection Abscesses in Mice. Antimicrobial Agents and Chemotherapy, 2005, 49, 3668-3675.	1.4	2
327	Defective acute inflammation in Crohn's disease. Lancet, The, 2006, 368, 577-578.	6.3	2
328	Introduction: Cytokines in the biotherapy of infectious diseases. Biotherapy (Dordrecht, Netherlands), 1994, 7, 149-150.	0.7	1
329	Candidaemia secondary to intravascular catheter colonisation? â€“ Authors' reply. Lancet, The, 2006, 367, 729.	6.3	1
330	Antibiotic Mixing through Impacted Bone Grafts Does Not Seem Indicated in Two-Stage Cemented Hip Revisions for Septic Loosening. HIP International, 2014, 24, 596-603.	0.9	1
331	Serological and Clinical one year follow-up of Patients with Erythema migrans treated in a Romanian Infectious Disease Hospital. Romanian Journal of Laboratory Medicine, 2014, 22, .	0.1	1
332	Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. European Journal of Immunology, 2001, 31, 2529.	1.6	1
333	Cost-effectiveness of prophylactic antibiotics to prevent pneumonia in patients treated with chemoradiotherapy (CRT) for locally advanced head and neck carcinoma (LAHNC).. Journal of Clinical Oncology, 2017, 35, 6075-6075.	0.8	1
334	Concerns about the external validity of the study â€˜prevalence of persistent symptoms after treatment for Lyme borreliosis: A prospective observational cohort studyâ€™-authorsÂ´ reply. Lancet Regional Health - Europe, The, 2022, 15, 100344.	3.0	1
335	NOD2 engagement induces proinflammatory cytokine production, but not apoptosis, in leukocytes isolated from patients with Crohn's disease. European Cytokine Network, 2008, 19, 185-9.	1.1	1
336	Failure of prescribers to adjust antibiotic dose to impaired renal function in daily clinical practice. British Journal of Clinical Pharmacology, 2002, 53, 557P-557P.	1.1	0
337	Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia. European Journal of Clinical Investigation 2004;34:94-99. European Journal of Clinical Investigation, 2004, 34, 322-322.	1.7	0
338	Summary and comments. Journal of Antimicrobial Chemotherapy, 2009, 63, i41-i43.	1.3	0
339	Caspase-1, but not ASC or NLRP3 inflammasome components, mediates IL-1beta activation and antifungal defense in disseminated candidiasis. Cytokine, 2009, 48, 120.	1.4	0
340	PS2-102. Cross-tolerance and priming between C-type lectin receptors and TLRs. Cytokine, 2011, 56, 92-93.	1.4	0
341	Host impairments in patients with neoplastic diseases. , 1998, 96, 1-32.		0